In silico investigations identified Butyl Xanalterate to competently target CK2α (CSNK2A1) for therapy of chronic lymphocytic leukemia
暂无分享，去创建一个
B. Alshehri | S. Mir | F. Alhumaydhi | H. Patel | A. Oyouni | Y. Hawsawi | S. Alsagaby | I. Ahmad | B. Alanazi | Yahya Madkhali | M. Mir | W. Alturaiki | Y. Hawsawi | W. Al Abdulmonem | Wael Alturaiki | Danish Iqbal | Y. Madkhali | I. Ahmad | Bader S Alanazi